The estimated Net Worth of Anthony Principi is at least 3.88 百万$ dollars as of 28 September 2020. Anthony Principi owns over 93,798 units of Harrow Health stock worth over 3,880,423$ and over the last 12 years Anthony sold HROW stock worth over 0$.
Sign up
Anthony Principi HROW stock SEC Form 4 insiders trading
Anthony has made over 1 trades of the Harrow Health stock since 2020, according to the Form 4 filled with the SEC. Most recently Anthony exercised 93,798 units of HROW stock worth 3,880,423$ on 28 September 2020.
The largest trade Anthony's ever made was exercising 93,798 units of Harrow Health stock on 28 September 2020 worth over 3,880,423$. On average, Anthony trades about 5,211 units every 0 days since 2013. As of 28 September 2020 Anthony still owns at least 93,798 units of Harrow Health stock.
You can see the complete history of Anthony Principi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Anthony Principi's mailing address?
Anthony's mailing address filed with the SEC is C/O HARROW HEALTH, INC., 102 WOODMONT BLVD., SUITE 610, NASHVILLE, TN, 37205.
Insiders trading at Harrow Health
Over the last 6 years, insiders at Harrow Health have traded over 1,363,111$ worth of Harrow Health stock and bought 1,487,560 units worth 12,882,479$ . The most active insiders traders include Management Inc. Opaleye、Mark L Baum、Andrew R. Boll. On average, Harrow Health executives and independent directors trade stock every 29 days with the average trade being worth of 3,323,914$. The most recent stock trade was executed by Management Inc. Opaleye on 25 April 2024, trading 20,000 units of HROW stock currently worth 199,400$.
What does Harrow Health do?
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
What does Harrow Health's logo look like?
Complete history of Anthony Principi stock trades at Cytocom Inc、Harrow Health
Harrow Health executives and stock owners
Harrow Health executives and other stock owners filed with the SEC include:
-
Mark Baum,
Chief Executive Officer, Director -
Andrew Boll,
Chief Financial Officer, Corporate Secretary -
John Saharek,
President of ImprimisRx -
Mark L. Baum J.D.,
CEO & Chairman -
Andrew R. Boll C.F.A., C.M.A., CFA, CMA,
CFO & Corp. Sec. -
John P. Saharek,
Pres of ImprimisRx -
Richard Lindstrom,
Director -
Robert Kammer,
Independent Chairman of the Board -
Dr. Robert J. Kammer D.D.S.,
Special Advisor -
R. Lawrence Van Horn,
Independent Director -
Teresa Sparks,
Independent Director -
Larry Dillaha,
Chief Medical Officer -
Kim Barratt,
Chief Talent Officer -
Dr. Larry M. Dillaha M.D.,
Chief Medical Officer -
David Moufarrège,
VP of Technology -
Jamie Webb,
Director of Communications & Investor Relations -
Andrew Livingston,
Chief Innovation Officer -
Dr. Dennis E Saadeh Pharm.D.,
Chief of Formulation Strategy -
David Moufarrège,
VP of Technology -
Lauren P Silvernail,
Director -
Stephen G Austin,
Director -
Anthony Principi,
Director -
Management Inc. Opaleye,
10% owner -
Perry J. Sternberg,
Director -
Martin A. Makary,
Director